|
ACBD7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.62925999999119E-05 |
| Normal-vs-Stage3 |
1.62447832963153E-12 |
| Normal-vs-Stage4 |
5.54578605260758E-12 |
| Stage1-vs-Stage2 |
2.049700E-02 |
| Stage1-vs-Stage3 |
8.582800E-01 |
| Stage1-vs-Stage4 |
8.172400E-01 |
| Stage2-vs-Stage3 |
5.148100E-02 |
| Stage2-vs-Stage4 |
3.148100E-02 |
| Stage3-vs-Stage4 |
7.337200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
2.09879999999441E-05 |
| Normal-vs-Asian |
1.29449999608511E-08 |
| Caucasian-vs-AfricanAmerican |
7.360400E-03 |
| Caucasian-vs-Asian |
6.307400E-01 |
| AfricanAmerican-vs-Asian |
1.069830E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62436730732907E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
1.675620E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.65367719517917E-12 |
| Normal-vs-Age(81-100Yrs) |
2.839900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.159600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.377600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.186800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.983000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.664600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.961600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.488300E-02 |
| Classical-VS-Follicular |
2.217900E-04 |
| Classical-VS-Other |
4.893000E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
1.570530E-04 |
| Tall-VS-Other |
1.028240E-01 |
| Tall-VS-Normal |
2.79050005325132E-09 |
| Follicular-VS-Other |
6.872800E-01 |
| Follicular-VS-Normal |
3.05020009250256E-10 |
| Other-VS-Normal |
1.289360E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
2.36999975200547E-10 |
| N0-vs-N1 |
1.816330E-02 |
|
|
